Malin (MLLNF) Intrinsic Value: Projected FCF: $0.00 (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLLNF Malin Corporation PLC MLLNF
17 GF Score
Price $6.40
View Full Analysis

What is Malin Intrinsic Value: Projected FCF?

Malin MLLNF 17 Intrinsic Value: Projected FCF is $0.00 as of Aug. 22, 2026. GuruFocus rates MLLNF with a GF Score™ of 17/100.

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2026-08-22), Malin's Intrinsic Value: Projected FCF is $0.00. The stock price of Malin is $6.40. Therefore, Malin's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Malin's Intrinsic Value: Projected FCF or its related term are showing as below:

MLLNF's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.59
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Malin  (OTCPK:MLLNF) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Malin's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=6.40/4.6400588867444
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Malin Intrinsic Value: Projected FCF Related Terms


Malin Intrinsic Value: Projected FCF Historical Data

* Premium members only.

The historical data trend for Malin's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malin Intrinsic Value: Projected FCF Chart

Malin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.62 2.71 -1.44 3.48

Malin Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.71 0.00 -1.44 0.00 3.48

MLLNF vs ZTS, UTHR, VTRS: Intrinsic Value: Projected FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Malin's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Malin Price-to-Projected-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Malin's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Malin's Price-to-Projected-FCF falls into.


MLLNF
17GF Score
Malin Corporation PLC MLLNF
Intrinsic Value: Projected FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Malin Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Malin's Free Cash Flow(6 year avg) = $-7.74.

Malin's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec24)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-7.7394285714286+202.304*0.8)/19.000
=4.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Intrinsic Value: Projected FCF of $0.00 mean?
Malin (MLLNF) has a Intrinsic Value: Projected FCF of $0.00 as of Aug. 22, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Malin and its competitors.
Is Malin's Intrinsic Value: Projected FCF too high?
Malin's current Intrinsic Value: Projected FCF is $0.00. Overall, Malin has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Malin's Intrinsic Value: Projected FCF compare to ZTS and UTHR?
Malin's Intrinsic Value: Projected FCF of $0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Intrinsic Value: Projected FCF is 1.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.59, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Malin and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malin's current Intrinsic Value: Projected FCF is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malin stock overvalued right now?
Malin (MLLNF) has a current Intrinsic Value: Projected FCF of $0.00. The current Intrinsic Value: Projected FCF is $0.00. Malin's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Malin (MLLNF), the current Intrinsic Value: Projected FCF is $0.00 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Malin Business Description

Address 50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.
17GF Score

Get the complete analysis for MLLNF

Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.40
Price